Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of imlifidase-enabled deceased donor kidney transplantation in highly sensitized patients
NL-OMON60646Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- Oct 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of imlifidase in end-stage kidney disease (ESKD) and chronic kidney disease (CKD) (3 cohorts), sponsored by Hansa Biopharma. Primary endpoint: 1-year graft failure-free survival. Started Oct 2022; status: completed.
02
Drugs
imlifidase
03
Conditions
end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60646.